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ABSTRACT
Bariatric surgery is currently the only treatment for obesity that is effective in both the
short and long term. Despite this, little is known about the mechanisms through which these
surgeries act. While no single critical system has yet been identified, a number of major
hypotheses have been proposed. One hypothesis is that adaptive hyperplasia of the intestines
following Roux-en-Y gastric bypass (RYGB) surgery is required in order to receive the
beneficial effects of the surgery. In this thesis I characterized the adaptive response of the
intestines following RYGB and showed that significant hyperplasia occurs in the intestinal
mucosa. In addition, I characterized the proliferation of enteroendocrine cells. I found that there
is an increase in the number, but not density, of glucagon-like-peptide 1, neurotensin, and
serotonin releasing cells, as well as an increase in both number and density of cholecystokinin
releasing cells, in the Roux and common limbs following RYGB. This could link adaptive
hyperplasia to increased circulating levels of these hormones, which has been implicated in a
reduction of food intake and an improvement in glucose homeostasis.
A second hypothesis that has been proposed states that RYGB and vertical sleeve
gastrectomy (VSG), two similar but ultimately different surgeries, work through a common
mechanism of action. In contrast to our observations in rats following RYGB, we found that
adaptive hyperplasia is absent following VSG. This leads to the conclusion that either RYGB
and VSG share a common mechanism that does not involve adaptive hyperplasia of the
intestines, or they do not share a common mechanism.
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CHAPTER 1: INTRODUCTION

1.1 The Obesity Epidemic
Obesity has increased at an alarming rate over the last 50 years. The first National Health
Examination Survey took data from 1960-1962 and showed that 31.5% of US adults over the age
of 20 were overweight (BMI25.0-29.9), and 13.4% were obese (BMI ≥ 30.0) 1. In 2012, the same
survey showed that over the previous 50 years the prevalence of overweight remained relatively
stable at 33.9%, but the prevalence of obesity in adults had more than doubled to 35.1% 2. In the
same series of surveys it was shown that from 1960-1962 the prevalence of obesity in children 617 years old ranged from 3.4% to 4.7% depending on subgroup 3. By 2012, the prevalence of
obesity in children aged 6-19 years had tripled to 16.9% 2. Due to the numerous health concerns
related to overweight and obesity 4, this has become a serious public health crisis, and there is an
increasing focus on research into effective ways to combat this epidemic.
While classical interventions such as dieting and counseling do work in the short term to
reduce obesity, surgical intervention remains the only treatment option that maintains a
significant reduction in obesity and related co-morbidities for longer than 5-10 years 5. Despite
this, little is known about how gastric bypass surgeries actually work to reduce body weight and
improve glucose homeostasis. In this thesis, I will review Roux-en-Y gastric bypass (RYGB) and
vertical sleeve gastrectomy (VSG) procedures, as well as potential mechanisms of action that are
currently being investigated. Following that, I will present my own data and relate it to two
major hypotheses that have recently been proposed. The first hypothesis states that adaptive
hyperplasia of the intestines following RYGB is required for the weight loss and improvement of
glucose homeostasis associated with the surgery. The second hypothesis states that RYGB and
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VSG share a common mechanism of action. My research will hopefully shed some light on the
validity of these hypotheses and push the field closer to the ultimate goal of an effective,
knifeless treatment for obesity.

1.2 Roux-en-Y Gastric Bypass
1.2.1 Introduction
Originally, Roux-en-Y gastric bypass (RYGB) was designed as a restrictive and
malabsorptive procedure to physically limit the amount of food that a person could ingest and
digest 6. While the physical re-arrangement of the gut does lead to some degree of physical
restriction, recent evidence suggests that food restriction alone cannot account for all of the
effects of RYGB 7. This has led to the investigation of other possible mechanisms through which
RYGB could be acting to maintain long term weight loss. Due to the complexity of the systems
that regulate energy balance in mammals, potential mechanisms of action are numerous and
include: a changed gut hormone secretion profile, changes to the intestinal microbiome,
alterations in central nervous system regulation of food intake and food preference, altered bile
acid secretions, adaptive hypertrophy of the gut, and increased energy expenditure 13.

1.2.2 History
Bariatric surgeries can be described as either restrictive or malabsorptive, with the former
reducing the amount of food one can store in the stomach, and the latter reducing the ability of
the intestines to absorb nutrients. Roux-en-Y gastric bypass was first described in 1967 by
Mason and Ito as both a restrictive and malabsorptive procedure designed to reverse obesity by
bypassing both the stomach and a significant portion of the intestines 6. This procedure was
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refined and then described in its current form by Torres in 1983 8 and slowly began to rise in
popularity as an effective treatment for obesity. Confidence in the procedure increased even
further in 1994 with the introduction of laparoscopic techniques that reduced mortality rates to
0.1% 9 and improved post-operative conditions for patients 10. Since then RYGB has continued
to increase in prevalence with over 150,000 surgeries being performed every year 11.

1.2.3 Procedure
RYGB surgical procedures have been outlined in detail previously 8,10. Briefly, RYGB
aims to alter the flow of nutrients from the esophagus directly into the jejunum, completely
bypassing the stomach and duodenum (Figure 1.1). Only a small gastric pouch with a volume of
about 5% of the original stomach remains between the esophagus and jejunum. The pyloric
sphincter is bypassed and food is therefore no longer able to be stored in the stomach for any
significant period of time before passing into the jejunum. The bypassed stomach and duodenum
are not removed, but are instead connected to the lower jejunum to maintain the flow of bile
acids and pancreatic juices into the intestines. This preserves the ability to digest food in the
shortened intestinal tract to prevent excessive malabsorption.

1.2.4 Efficacy
Patients undergoing RYGB have been shown to lose more than 30% body weight in the
first year after surgery 12. There is a slight trend towards weight regain after the first few years,
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Figure 1.1 Schematic illustration of the pre- (a) and postoperative anatomy after Roux-en-Y
gastric bypass (b) and Vertical Sleeve Gastrectomy (c). Image reproduced with permission 13.

but even after 15 years RYGB patients show a 25% body weight decrease on average when
compared to pre-surgical levels. These results have led the National Institutes of Health to
classify bariatric surgery as the only known effective long term treatment for obesity 5. Since
1991, no other treatment has obtained this distinction.
In addition to maintaining long term weight loss, RYGB has been shown to be effective
in reducing a large number of obesity related co-morbidities including type 2 diabetes, heart
disease, various cancers, sleep apnea, high blood pressure, high cholesterol, and joint problems
14–16

. Perhaps the most significant of these is the improvement seen in patients with type 2

diabetes. In one study, complete resolution of type 2 diabetes was observed in 76.8% of RYGB
patients 16. While improvements in glycemic control can be expected after weight loss, it has
been suggested that resolution of type 2 diabetes occurs rapidly after the procedure before any
significant weight loss has occurred 17. While this idea has since been contested 18–20, this was the
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first indication that RYGB surgery may not just be purely restrictive and malabsorptive, but may
in fact cause significant changes in the metabolism of patients.

1.2.5 Animal models
Despite the wealth of studies describing the beneficial effects of RYGB, there is little
known about the actual mechanisms through which RYGB acts. In recent years a number of labs
have developed their own RYGB models using obese rats or mice to begin investigating
potential mechanisms of action. These various RYGB models have consistently shown effects
similar to those seen in humans including weight loss, improvement in glycemic control, and
elevated postprandial secretion of gastric hormones such as peptide YY (PYY) and glucagon-like
peptide 1 (GLP-1) 21. Unfortunately, there is a severe lack of standardization in the RYGB
models used by different labs, and therefore comparison between groups has been difficult.
One major difference across RYGB models is the size of the gastric pouch. In humans,
the gastric pouch is left as small as possible, with a resulting volume of less than 5% of the
original stomach 22. In rats, the size of the gastric pouch ranges from less than 5% to more than
20% of the original volume 23. This is the result of the technical difficulties involved in creating
such a small gastric pouch in rats. While a skilled micro-surgeon can successfully create a small
gastric pouch, a review of surgical techniques has shown that many labs use staplers to transect
the stomach, preventing fine control over the size of the gastric pouch and leaving up to 20% of
the original stomach volume 24. The effects of a variable gastric pouch size have not been
carefully studied in rat models of RYGB, but a larger pouch could lead to slower transportation
of food to the intestines, which in turn could alter the physiological response to a meal. In
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humans it has been shown that gastric pouch size does affect weight loss, with a smaller pouch
having the best outcome for patients 25.
Another source of variation between RYGB models is in the length of the intestinal
limbs. A review of rat models showed that the roux limb ranged from 10 cm to 50 cm, the
biliopancreatic limb length ranged from 10 cm to 40 cm, and the common limb ranged from 18
cm to 34 cm 23. Unfortunately, in humans there is also a large amount of variation in what is
considered to be the optimal limb length, so there is no human equivalent to base a standardized
rodent model on 26,27. Differences in intestinal length necessarily alter the degree of
malabsorption experienced by rats after RYGB. However, malabsorption has not been shown to
be a major mechanism through which RYGB acts, so it is unknown how big of an impact limb
length has on surgical outcomes. The intestines are also a major endocrine organ, and variations
in limb length may lead to variations in the hormonal response to an ingested meal.
In addition to the variation in surgical techniques, there is significant variation in the
mortality rates reported across different RYGB models. Mortality rates range from as low as
0.1% to as high as 35% 23, but on average mortality rates are extremely high compared to the
human mortality rate of 0.1% 9. Excessive mortality rates are concerning in that they call into
question surgeon skill, and therefore how healthy experimental animals are even when they
survive surgery. Standardization of RYGB surgical techniques will hopefully make it easier to
train surgeons and decrease variation among different research groups.

1.3 Vertical Sleeve Gastrectomy
Vertical sleeve gastrectomy (VSG) has a more varied history than RYGB, but was also
described in its current form as a purely restrictive procedure in 2001 28. VSG aims to reduce the
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volume of the stomach while maintaining the normal flow of nutrients through the gut.
Compared to RYGB, VSG is relatively simple. 80% of the stomach is removed along the greater
curvature, leaving only a small channel of tissue along the lesser curvature. The remaining tissue
is sutured closed resulting in a tube like structure called the gastric sleeve (Figure 1.1). This
technique was originally developed in 1999 in an attempt to reduce complications in obese
patients that were at high risk when undergoing a procedure known as the duodenal switch 29.
Patients would first undergo VSG to induce initial weight loss. About six months later, once their
BMI was reduced to acceptable levels, they would be given the more invasive duodenal switch
procedure. To the surprise of the surgeons, VSG alone was effective in maintaining long term
weight loss without the need for a duodenal switch. VSG has since become a common weight
loss surgery due to its less-invasive nature, and has recently surpassed RYGB in popularity 11.
In addition to maintaining long term weight loss, VSG appears to induce all of the
metabolic changes observed after RYGB. Obese patients with type 2 diabetes tend to have rapid
improvement in all markers associated with diabetes, possibly independent of weight loss 30.
The hormonal profile of patients with VSG also mirrors RYGB, with postprandial increases in
gastric hormones such as GLP-1, PYY, and amylin 31. The striking similarities in the outcomes
of RYGB and VSG have led many researchers to believe that the two surgeries share a similar
mechanism of action 32, and that both can be used interchangeably in rodent models for research
33

. VSG has since become popular among researchers due to the simpler surgical techniques

involved. This is especially true in mouse models where the microsurgery involved in
performing RYGB is beyond the skill of many surgeons, and VSG is the only reasonable
substitution.
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1.4 Mechanisms of Action
1.4.1 Physical restriction
Physical restriction of food intake was conventionally believed to be the mechanism
through which bariatric surgeries elicit their effects. It was hypothesized that a smaller stomach
would fill more quickly and create mechanical pressure that would lead to earlier satiation after a
meal. Even as recently as 2008 it was thought that increased gastric pressure was a possible
mechanism of action for VSG 34. However, recent data has shown that neither VSG nor RYGB
seem to rely on physical restriction for any of their major effects.
Comparisons with a procedure known as the adjustable gastric band (AGB) have been the
most useful in determining the role of physical restriction in bariatric surgery. Unlike VSG and
RYGB, AGB reduces stomach volume without inflicting any surgical trauma on the digestive
tract of the patient. This is performed by inserting a silicone band that is fitted around the
stomach near the esophageal junction (Figure 1.2). The band is filled with saline and becomes
enlarged, compressing the stomach and limiting food storage to a small gastric pouch anterior to
the band. After AGB, total gastric volume available for food storage is reduced to around 15-20
ml 35, about the same volume as the remaining gastric pouch after RYGB, and much smaller than
the 150-200 ml gastric sleeve left after VSG. Despite this significant physical restriction, studies
have shown that AGB cannot achieve the level of weight loss observed after RYGB and VSG in
either the short term or long term 7.
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Figure 1.2 Schematic of modern placement of an adjustable gastric band. This fixed band
creates a small meal-sized pouch above the band—a restrictive procedure. The modern surgical
technique mandates secure fixation of the LAGB immediately beneath the gastroesophageal
junction (GE). Image reproduced with permission 36.

Additional evidence against a restrictive mechanism is that both VSG and RYGB rats
have been shown to be able to increase food intake to presurgical levels in order to increase body
weight when necessary. After calorie restriction, VSG rats have reduced body weight and will
overeat to return to a healthy weight once food is returned 37. It has also been shown that
pregnant and lactating VSG rats are able to increase food intake in response to an increased
demand for energy 38. In a study performed by our own lab, we showed that RYGB rats are also
capable of increasing food intake to increase body weight. After intracerebroventricular infusions
of the melanocortin-3/4 receptor antagonist SHU9119, RYGB rats increased their daily food
intake by 100%, and increased fat mass by 15% over 2 weeks 39. These studies found that even
though meal size may be restricted after VSG and RYGB, rodents maintain the ability to increase
food intake by simply increasing meal frequency. It is therefore unlikely that weight loss is due
to purely physical restriction.
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1.4.2 Gastric Hormones
One alternative to physical restriction is the hypothesis that both RYGB and VSG alter
communication between the gut and other organs leading to changes in the regulation of body
weight and glucose homeostasis. The gut is one of the most complex systems in mammals and
relies heavily on both endocrine and neural signaling to communicate with other organs in the
body. The stomach and intestines secrete over 20 different peptide hormones that regulate a
number of functions such as appetite control, insulin and glucagon secretion, gut motility,
intestinal blood flow, and cell proliferation. Neural signaling in the gut is also complex with both
heavy innervation by the autonomic nervous system (ANS) and a large independent network of
neurons known as the enteric nervous system (ENS). These systems play a large role in
regulating food intake, metabolism, and energy balance, all of which are dysregulated in obesity.
Disruption of endocrine and/or neural signaling after gastric bypass may be responsible for the
improvements seen in patients after surgery.
The earliest observations involving endocrine changes after gastric bypass involved the
hormones ghrelin and GLP-1. Ghrelin is a peptide hormone secreted by cells in the stomach 40
that has been shown to increase food intake 41,42 and reduce insulin sensitivity 43 when
administered exogenously. These effects promote obesity and diabetes, and it was thought that
by removing the stomach after gastric bypass, there would be a reduction in ghrelin and therefore
a decrease in food intake and an increase in insulin sensitivity. It was indeed found that ghrelin is
reduced after VSG 44. However, this same study found that VSG was fully effective in ghrelin
deficient mice, indicating that ghrelin signaling is not required for the full effects of VSG. The
same group also found that ghrelin signaling was not significantly altered after RYGB, and is
therefore unlikely to play a role in that surgery either 44.
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GLP-1 is another hormone that received early attention when it was found to be elevated
postprandially in patients undergoing either RYGB 45–49 or VSG 17,50. GLP-1 is an incretin
hormone secreted by L-cells in the lower intestine that acts to reduce food intake and increase
insulin secretion 51,52, two effects that are the hallmark of gastric bypass. In addition, a
correlation was found between patients who had the most weight loss and patients who had the
most elevated GLP-1 following RYGB 53,54. Elevated GLP-1 following a meal in RYGB patients
was therefore hypothesized to be one of the factors responsible for the beneficial effects of the
surgery. Unfortunately, this hypothesis has not been well supported by the data. RYGB was
found to be fully effective in animals that were either GLP-1 receptor (GLP-1r) deficient or
receiving intracerebroventricular infusions of GLP-1r antagonists 55. Additionally, it was shown
that VSG is fully effective in GLP-1r deficient mice 56. However, these studies have only looked
at GLP-1 independently, despite the fact that the gut secretes a number of other hormones. It is
still possible that GLP-1 signaling works in concert with other hormones such as cholecystokinin
(CCK), PYY, glucagon-like-peptide 2 (GLP-2), neurotensin, somatostatin, gastric inhibitory
peptide (GIP), or any of the other gastric hormones.

1.4.3 CNS control of appetite
The central nervous system also plays a role in the regulation of energy balance and
metabolism. The gut is heavily innervated and is able to communicate with the brain through the
vagus nerve. Through this gut-brain axis, the vagus nerve is able to relay information when
stimulated by signaling molecules such as ghrelin 57, CCK 58, and PYY 59, as well as information
about gastric distension and pressure 60, to help control meal size and appetite. This information
is sent to areas of the brain involved in appetite control and feeding behavior, such as the area
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postrema (AP), nucleus of the solitary tract (NTS), parabrachial nucleus (PBN), hypothalamus,
and the central amygdaloid nucleus (CeA) 61. Specific neural pathways that have been shown to
be important in the regulation of appetite and food intake include the melanocortin system, the
neuropeptide-Y-pro-opiomelanocortin (NPY-POMC) neural circuit in the hypothalamus, and the
NTS-PBN-CeA circuit driven by calcitonin-gene-related peptide (CGRP) neurons. These
systems have been shown to be extremely powerful, and when manipulated can induce either
severe obesity 62 or complete loss of food intake 63, even to the point of death.
It is unknown exactly how RYGB and VSG interfere with these regulatory systems.
There is conflicting evidence regarding melanocortin signaling, with one study showing it to be
necessary for mice to receive the beneficial effects of RYGB 64, but another showing it to not be
required for VSG in rats 65. It is unclear whether this is a species specific difference, or a
difference between RYGB and VSG surgery, but more information will be necessary to
determine if melanocortin signaling plays an important role in either surgery. The NTS-PBNCeA CGRP circuit has not been well studied after RYGB, but has begun to be investigated due
to its profound ability to induce anorexia. Our lab has found a correlation between reduced food
intake following RYGB and increased signaling through this pathway (data unpublished), but a
causative role for this pathway has yet to be shown. Additional evidence supporting CNS
involvement in the beneficial effects of gastric bypass can be found in vagotomy studies. It has
been shown that preservation of the vagus nerve following RYGB is necessary to receive the full
weight loss effects of the surgery 66,67, suggesting that some signal is being sent through the
vagus nerve to help reduce appetite and food intake. It remains to be seen how exactly gastric
bypass causes altered signals to the CNS.
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1.4.4 Bile acids
A change in bile acid (BA) secretion has also been proposed as a potential mechanism of
action for RYGB and VSG surgeries. In addition to aiding in the digestion of fatty acids in the
small intestines, BAs work in an endocrine fashion to help regulate metabolism and energy
expenditure. The most studied receptor for BAs is TGR5, which is expressed in a number of
different tissues. In the intestines, TGR5 activation leads to increased secretion of GLP-1 and
PYY from L-cells 68. As mentioned earlier, these are incretin hormones which stimulate the
release of insulin and aid in maintaining proper blood glucose levels. In addition, TGR5 is
expressed directly on beta cells within pancreatic islets of the pancreas, and TGR5 agonists have
been shown to cause an increase in insulin secretion 69. In brown adipose tissue (BAT), TGR5
activation leads to increased energy expenditure through thermogenesis 70, an effect which is
believed to help protect against obesity. BAs have also been shown to work through the FXR
receptor in the intestines to promote the release of FGF19, which is important in the regulation of
glucose and lipid disposal 71. Together, this evidence supports the positive role of BAs in
regulating metabolism and glucose homeostasis.
Circulating BA levels were found to be reduced in obese patients when compared to lean,
an effect which is normalized by both RYGB and VSG surgeries 72,73. This observation has led to
the proposal that increased BA secretion following gastric bypass may play a causal role in
subsequent weight loss and diabetes resolution. Unfortunately, this claim has not been well
supported by the data. One human study showed no significant increases in BA concentrations
until a year after surgery 74, which conflicts with the almost immediate improvements
experienced by most patients. More rigorous TGR5 loss of function studies will be needed to
elucidate the role of signaling through this receptor following gastric bypass. One study looking
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at the role of the FXR receptor showed more promising results. VSG was found to be ineffective
at maintaining weight loss in FXR-ko mice compared to wild type 75. Interestingly, Ryan et al 75
found genotype specific changes in the microbiota of the mice following VSG, which may
suggest that FXR signaling works through the microbiome rather than direct signaling to any
specific tissue. More studies will be necessary to determine whether or not BAs actually play a
causal role in the beneficial effects of gastric bypass.

1.4.5 Microbiome
Recently, changes to the microbiome have been suggested as another possible mechanism
of action for gastric bypass. Early studies showed that the intestinal flora of obese mice differs
from lean mice with a significant increase in Firmicutes and decrease in Bacteroidetes 76.
Interestingly, this same effect was later found in humans 77, and was found to be reversed by
weight loss induced by RYGB 78. It is unknown whether or not this alteration in microbiota is
simply due to the increased energy intake of obese subjects, or if it plays a more causative role in
the development of obesity. However, some evidence supporting the latter was found in
experiments with germ free mice. Fecal transplants from obese mice into germ free lean mice
caused obesity even when the germ free mice were given a standard low fat diet, while
transplants from lean mice had no significant effect on weight gain 79,80.
There are a number of ways that intestinal flora are able to interact with the host to
influence metabolism and energy homeostasis. The most obvious method is an increased ability
to digest and extract energy from carbohydrates through fermentation. However, an obese
microbiota was found even in mice fed a high fat and nearly carbohydrate free diet, suggesting
increased energy availability from fermentation is not a major factor 81. It has since been shown
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that the microbiome may interact with the host through other mechanisms. One such mechanism
is an increase in the presence of lipopolysaccharide (LPS), a molecule found in the cell wall of
gram-negative bacteria. Increased circulating levels of LPS have been found in obese mice fed a
high fat diet 82, and are associated with metabolic endotoxemia, a state of chronic low grade
inflammation of adipose tissue that is thought to be associated with the development of obesity.
Changes in intestinal flora have also been linked to changes in gene expression of receptors
involved in fatty acid metabolism and storage. Angiopoietin-related protein 4 (Angptl4) is a
protein expressed in skeletal muscle and adipose tissue that inhibits the uptake of fatty acids and
promotes fatty acid oxidation, promoting a lean phenotype. This protein was found to be
decreased in normal mice compared to germ free mice, suggesting that this gene is responsive to
the intestinal microbiota 83.
While there is a significant amount of corollary data relating specific differences in
microbial phenotype between obese and lean subjects, very little evidence has been generated
suggesting an actual causative role of the microbiome in the generation or reduction of obesity.
Some studies using probiotics to alter the intestinal flora of obese humans showed modest results
84

, however the actual composition of the microbiome was never investigated in these studies and

it is therefore unknown what effect the probiotics actually had. More work with probiotics and
antibiotics will be needed to determine if the microbiome can actually be used to prevent or
reverse obesity, and whether or not this “reprogramming” of the intestinal flora plays a crucial
role in gastric bypass.
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1.5 Conclusions
It is clear that the gut is an enormously complex system with numerous overlapping, and
probably redundant, regulatory mechanisms. The massive reconstruction of the gut following
gastric bypass surgeries interferes with most, if not all, of these mechanisms and is therefore
quite difficult to study. While no individual mechanism has been found to be required to obtain
the beneficial effects of RYGB or VSG, a number of critical systems have been identified. It is
likely that the full effect of gastric bypass does not rely on a single mechanism, but is instead due
to multiple systems changing in concert. Identifying these systems is an arduous process, but will
hopefully lead to treatments for obesity that are just as effective as gastric bypass without the
need for such invasive and dangerous surgery.

1.6 References
1.

Fryar, C. D., Carroll, M. D., Ogden, C. L. & Others. Prevalence of overweight, obesity,
and extreme obesity among adults: United States, trends 1960--1962 through 2009--2010.
Hyattsville, MD: National Center for Health Statistics (2012).

2.

Ogden, C. L., Carroll, M. D., Kit, B. K. & Flegal, K. M. Prevalence of childhood and
adult obesity in the United States, 2011-2012. JAMA 311, 806–814 (2014).

3.

Flegal, K. M. & Troiano, R. P. Changes in the distribution of body mass index of adults
and children in the US population. Int. J. Obes. Relat. Metab. Disord. 24, 807–818
(2000).

4.

Reilly, J. J. et al. Health consequences of obesity. Arch. Dis. Child. 88, 748–752 (2003).

5.

Hubbard, V. S. & Hall, W. H. Gastrointestinal Surgery for Severe Obesity. Obes. Surg. 1,
257–265 (1991).

6.

Mason, E. E. & Ito, C. Gastric bypass in obesity. Surg. Clin. North Am. 47, 1345–1351
(1967).

7.

Franco, J. V. A., Ruiz, P. A., Palermo, M. & Gagner, M. A review of studies comparing
three laparoscopic procedures in bariatric surgery: sleeve gastrectomy, Roux-en-Y gastric
bypass and adjustable gastric banding. Obes. Surg. 21, 1458–1468 (2011).

16

8.

Torres, J. C., Oca, C. F. & Garrison, R. N. Gastric bypass: Roux-en-Y gastrojejunostomy
from the lesser curvature. South. Med. J. 76, 1217–1221 (1983).

9.

Zhao, Y. & Encinosa, W. Bariatric surgery utilization and outcomes in 1998 and 2004.
2007 (2007). at <http://www.ncbi.nlm.nih.gov/books/NBK63485>

10.

Wittgrove, A. C., Clark, G. W. & Tremblay, L. J. Laparoscopic Gastric Bypass, Roux-enY: Preliminary Report of Five Cases. Obes. Surg. 4, 353–357 (1994).

11.

Buchwald, H. & Oien, D. M. Metabolic/bariatric surgery worldwide 2011. Obes. Surg.
23, 427–436 (2013).

12.

Sjöström, L. et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N.
Engl. J. Med. 357, 741–752 (2007).

13.

Lutz, T. A. & Bueter, M. The physiology underlying Roux-en-Y gastric bypass: a status
report. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307, R1275–91 (2014).

14.

Kokkinos, A. et al. Improvement in cardiovascular indices after Roux-en-Y gastric
bypass or sleeve gastrectomy for morbid obesity. Obes. Surg. 23, 31–38 (2013).

15.

Christou, N. V., Lieberman, M., Sampalis, F. & Sampalis, J. S. Bariatric surgery reduces
cancer risk in morbidly obese patients. Surg. Obes. Relat. Dis. 4, 691–695 (2008).

16.

Buchwald, H. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292,
1724–1737 (2004).

17.

Chambers, A. P. et al. Weight-independent changes in blood glucose homeostasis after
gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 141, 950–958
(2011).

18.

Lingvay, I., Guth, E., Islam, A. & Livingston, E. Rapid improvement in diabetes after
gastric bypass surgery: is it the diet or surgery? Diabetes Care 36, 2741–2747 (2013).

19.

Lips, M. A. et al. Calorie restriction is a major determinant of the short-term metabolic
effects of gastric bypass surgery in obese type 2 diabetic patients. Clin. Endocrinol. 80,
834–842 (2014).

20.

Jackness, C. et al. Very low-calorie diet mimics the early beneficial effect of Roux-en-Y
gastric bypass on insulin sensitivity and β-cell Function in type 2 diabetic patients.
Diabetes 62, 3027–3032 (2013).

21.

Ashrafian, H. et al. Metabolic surgery: an evolution through bariatric animal models.
Obes. Rev. 11, 907–920 (2010).

17

22.

Madan, A. K., Harper, J. L. & Tichansky, D. S. Techniques of laparoscopic gastric
bypass: on-line survey of American Society for Bariatric Surgery practicing surgeons.
Surg. Obes. Relat. Dis. 4, 166–72; discussion 172–3 (2008).

23.

Seyfried, F., le Roux, C. W. & Bueter, M. Lessons learned from gastric bypass operations
in rats. Obes. Facts 4 Suppl 1, 3–12 (2011).

24.

Bueter, M., Abegg, K., Seyfried, F., Lutz, T. A. & le Roux, C. W. Roux-en-Y gastric
bypass operation in rats. J. Vis. Exp. e3940 (2012).

25.

Roberts, K. et al. Size matters: gastric pouch size correlates with weight loss after
laparoscopic Roux-en-Y gastric bypass. Surg. Endosc. 21, 1397–1402 (2007).

26.

Gleysteen, J. J. Five-year outcome with gastric bypass: Roux limb length makes a
difference. Surg. Obes. Relat. Dis. 5, 242–7; discussion 247–9 (2009).

27.

Lee, S., Sahagian, K. G. & Schriver, J. P. Relationship between varying Roux limb
lengths and weight loss in gastric bypass. Curr. Surg. 63, 259–263 (2006).

28.

De Csepel, J. et al. Laparoscopic biliopancreatic diversion with a duodenal switch for
morbid obesity: a feasibility study in pigs. J. Laparoendosc. Adv. Surg. Tech. A 11, 79–
83 (2001).

29.

Kim, W.-W. et al. Laparoscopic vs. open biliopancreatic diversion with duodenal switch:
a comparative study. J. Gastrointest. Surg. 7, 552–557 (2003).

30.

Rizzello, M. et al. Early postoperative insulin-resistance changes after sleeve
gastrectomy. Obes. Surg. 20, 50–55 (2010).

31.

Basso, N. et al. First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY
changes 72 h after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis.
Surg. Endosc. 25, 3540–3550 (2011).

32.

Stefater, M. A., Wilson-Pérez, H. E., Chambers, A. P., Sandoval, D. A. & Seeley, R. J.
All bariatric surgeries are not created equal: insights from mechanistic comparisons.
Endocr. Rev. 33, 595–622 (2012).

33.

Pressler, J. W. et al. Vertical sleeve gastrectomy restores glucose homeostasis in
apolipoprotein A-IV KO mice. Diabetes (2014). doi:10.2337/db14-0825

34.

Yehoshua, R. T. et al. Laparoscopic sleeve gastrectomy--volume and pressure
assessment. Obes. Surg. 18, 1083–1088 (2008).

35.

Miller, K. & Hell, E. Laparoscopic surgical concepts of morbid obesity. Langenbecks.
Arch. Surg. 388, 375–384 (2003).

18

36.

Burton, P. R. & Brown, W. A. The mechanism of weight loss with laparoscopic
adjustable gastric banding: induction of satiety not restriction. Int. J. Obes. 35 Suppl 3,
S26–30 (2011).

37.

Stefater, M. A. et al. Sleeve gastrectomy induces loss of weight and fat mass in obese
rats, but does not affect leptin sensitivity. Gastroenterology 138, 2426–36, 2436.e1–3
(2010).

38.

Grayson, B. E., Schneider, K. M., Woods, S. C. & Seeley, R. J. Improved rodent
maternal metabolism but reduced intrauterine growth after vertical sleeve gastrectomy.
Sci. Transl. Med. 5, 199ra112 (2013).

39.

Mumphrey, M. B. et al. Reversible hyperphagia and obesity in rats with gastric bypass by
central MC3/4R blockade. Obesity 22, 1847–1853 (2014).

40.

Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach.
Nature 402, 656–660 (1999).

41.

Tschöp, M., Smiley, D. L. & Heiman, M. L. Ghrelin induces adiposity in rodents. Nature
407, 908–913 (2000).

42.

Wren, A. M. et al. Ghrelin enhances appetite and increases food intake in humans. J.
Clin. Endocrinol. Metab. 86, 5992 (2001).

43.

Delhanty, P. J. D. & van der Lely, A. J. Ghrelin and glucose homeostasis. Peptides 32,
2309–2318 (2011).

44.

Chambers, A. P. et al. The effects of vertical sleeve gastrectomy in rodents are ghrelin
independent. Gastroenterology 144, 50–52.e5 (2013).

45.

Le Roux, C. W. et al. Gut hormone profiles following bariatric surgery favor an anorectic
state, facilitate weight loss, and improve metabolic parameters. Ann. Surg. 243, 108–114
(2006).

46.

Laferrère, B. et al. Incretin levels and effect are markedly enhanced 1 month after Rouxen-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30,
1709–1716 (2007).

47.

Korner, J., Bessler, M., Inabnet, W., Taveras, C. & Holst, J. J. Exaggerated glucagon-like
peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated
with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg. Obes. Relat. Dis.
3, 597–601 (2007).

48.

Morínigo, R. et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric
bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. Metab. 91, 1735–1740
(2006).
19

49.

Rodieux, F., Giusti, V., D’Alessio, D. A., Suter, M. & Tappy, L. Effects of gastric bypass
and gastric banding on glucose kinetics and gut hormone release. Obesity 16, 298–305
(2008).

50.

Peterli, R. et al. Improvement in Glucose Metabolism After Bariatric Surgery:
Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Sleeve
Gastrectomy: A Prospective Randomized Trial. Ann. Surg. 250, 234 (2009).

51.

Drucker, D. J. Biological actions and therapeutic potential of the glucagon-like peptides.
Gastroenterology 122, 531–544 (2002).

52.

Mortensen, K., Christensen, L. L., Holst, J. J. & Orskov, C. GLP-1 and GIP are
colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 114, 189–
196 (2003).

53.

Le Roux, C. W. et al. Gut hormones as mediators of appetite and weight loss after Rouxen-Y gastric bypass. Ann. Surg. 246, 780–785 (2007).

54.

Umeda, L. M. et al. Early improvement in glycemic control after bariatric surgery and its
relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients.
Obes. Surg. 21, 896–901 (2011).

55.

Ye, J. et al. GLP-1 receptor signaling is not required for reduced body weight after
RYGB in rodents. Am. J. Physiol. Regul. Integr. Comp. Physiol. 306, R352–62 (2014).

56.

Wilson-Pérez, H. E. et al. Vertical sleeve gastrectomy is effective in two genetic mouse
models of glucagon-like Peptide 1 receptor deficiency. Diabetes 62, 2380–2385 (2013).

57.

Date, Y. et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and
growth hormone secretion in rats. Gastroenterology 123, 1120–1128 (2002).

58.

Smith, G. P., Jerome, C. & Norgren, R. Afferent axons in abdominal vagus mediate
satiety effect of cholecystokinin in rats. Am. J. Physiol. 249, R638–41 (1985).

59.

Koda, S. et al. The Role of the Vagal Nerve in Peripheral PYY3–36-Induced Feeding
Reduction in Rats. Endocrinology 146, 2369–2375 (2005).

60.

Phillips, R. J. & Powley, T. L. Gastric volume rather than nutrient content inhibits food
intake. Am. J. Physiol. 271, R766–9 (1996).

61.

Schwartz, M. W., Woods, S. C., Porte, D., Jr, Seeley, R. J. & Baskin, D. G. Central
nervous system control of food intake. Nature 404, 661–671 (2000).

62.

Huszar, D. et al. Targeted disruption of the melanocortin-4 receptor results in obesity in
mice. Cell 88, 131–141 (1997).

20

63.

Wu, Q., Boyle, M. P. & Palmiter, R. D. Loss of GABAergic signaling by AgRP neurons
to the parabrachial nucleus leads to starvation. Cell 137, 1225–1234 (2009).

64.

Hatoum, I. J. et al. Melanocortin-4 receptor signaling is required for weight loss after
gastric bypass surgery. J. Clin. Endocrinol. Metab. 97, E1023–31 (2012).

65.

Mul, J. D. et al. Effect of vertical sleeve gastrectomy in melanocortin receptor 4-deficient
rats. Am. J. Physiol. Endocrinol. Metab. 303, E103–10 (2012).

66.

Bueter, M. et al. Vagal sparing surgical technique but not stoma size affects body weight
loss in rodent model of gastric bypass. Obes. Surg. 20, 616–622 (2010).

67.

Hao, Z. et al. Vagal innervation of intestine contributes to weight loss After Roux-en-Y
gastric bypass surgery in rats. Obes. Surg. 24, 2145–2151 (2014).

68.

Thomas, C. et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell
Metab. 10, 167–177 (2009).

69.

Kumar, D. P. et al. Activation of transmembrane bile acid receptor TGR5 stimulates
insulin secretion in pancreatic β cells. Biochem. Biophys. Res. Commun. 427, 600–605
(2012).

70.

Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular
thyroid hormone activation. Nature 439, 484–489 (2006).

71.

Schaap, F. G. Role of fibroblast growth factor 19 in the control of glucose homeostasis.
Curr. Opin. Clin. Nutr. Metab. Care 15, 386–391 (2012).

72.

Ahmad, N. N., Pfalzer, A. & Kaplan, L. M. Roux-en-Y gastric bypass normalizes the
blunted postprandial bile acid excursion associated with obesity. Int. J. Obes. 37, 1553–
1559 (2013).

73.

Myronovych, A. et al. Vertical sleeve gastrectomy reduces hepatic steatosis while
increasing serum bile acids in a weight-loss-independent manner. Obesity 22, 390–400
(2014).

74.

Steinert, R. E. et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year
prospective randomized pilot trial. Obesity 21, E660–8 (2013).

75.

Ryan, K. K. et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy.
Nature 509, 183–188 (2014).

76.

Ley, R. E. et al. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. U. S. A. 102,
11070–11075 (2005).

21

77.

Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut
microbes associated with obesity. Nature 444, 1022–1023 (2006).

78.

Furet, J.-P. et al. Differential adaptation of human gut microbiota to bariatric surgeryinduced weight loss: links with metabolic and low-grade inflammation markers. Diabetes
59, 3049–3057 (2010).

79.

Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for
energy harvest. Nature 444, 1027–1031 (2006).

80.

Turnbaugh, P. J., Bäckhed, F., Fulton, L. & Gordon, J. I. Diet-induced obesity is linked to
marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe
3, 213–223 (2008).

81.

Cani, P. D. et al. Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced
Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice. Diabetes 57,
1470–1481 (2008).

82.

Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes
56, 1761–1772 (2007).

83.

Bäckhed, F. et al. The gut microbiota as an environmental factor that regulates fat
storage. Proc. Natl. Acad. Sci. U. S. A. 101, 15718–15723 (2004).

84.

Delzenne, N. M., Neyrinck, A. M., Bäckhed, F. & Cani, P. D. Targeting gut microbiota in
obesity: effects of prebiotics and probiotics. Nat. Rev. Endocrinol. 7, 639–646 (2011).

22

CHAPTER 2: ROUX-EN-Y GASTRIC BYPASS SURGERY INCREASES NUMBER BUT
NOT DENSITY OF CCK-, GLP-1-, 5-HT-, AND NEUROTENSIN-EXPRESSING
ENTEROENDOCRINE CELLS IN RATS

2.1 Introduction
Gastrointestinal hormones play a major role in the control of appetite and can cause either
orexigenic or anorexigenic behaviors by acting through the gut-brain axis 1–4. These hormones
are released by endocrine cells in the stomach and intestines in order to relay nutritional
information about recently consumed food to the brain. An increase in the release of
anorexigenic hormones, and/or a decrease in the release of orexigenic hormones, has long been
considered a mechanism through which RYGB may act to promote weight loss 5. Support for
this idea includes the observation that after RYGB in humans there is an increase in the
postprandial circulation of the lower gut hormones GLP-1 and PYY 6–8. These are anorexigenic
hormones produced by L-cells in the lower gut 9. However, despite a high level of correlation
between weight loss and circulating levels of these hormones 10,11, there is still no causative
evidence to suggest that this is a major mechanism of action for RYGB.
In addition to GLP-1 and PYY, the lower gut has significant populations of
enteroendocrine cells that produce other hormones such as CCK, serotonin (5-HT), and
neurotensin. CCK was the first gastrointestinal hormone shown to have an effect on satiation 12.
The role of CCK in mediating weight loss after RYGB has been controversial due to the fact that
early studies found no change in circulating levels of CCK in either humans or rodents 13,14.
However, since then, there have been a number of studies showing clear increases in circulating
CCK following RYGB 5,15–17. Despite this contradictory data, we believe that altered CCK levels
This chapter previously appeared as Mumphrey, M. B., Patterson, L. M., Zheng, H. & Berthoud, H.-R.
Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and
neurotensin-expressing enteroendocrine cells in rats. Neurogastroenterol. Motil. 25, e70–9 (2013). It is
reprinted by permission of John Wiley and Sons.
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have the potential to play some role after RYGB. The data surrounding 5-HT and neurotensin
have been even less clear, but as lower gut hormones we suspected that they should be subjected
to the same stimuli as GLP-1, PYY, and CCK, and are therefore worth investigating.
There have been no real attempts at determining the mechanism through which RYGB
increases circulating levels of the lower gut hormones. It is possible that there is an increase in
releasing stimuli, an increase in the number of hormone releasing cells, or a decrease in the rate
at which the hormones are broken down in circulation. An increase in the number of hormone
releasing cells is of particular interest due to observations made in mouse models of short bowel
syndrome (SBS); a procedure that is similar in many ways to RYGB. In one model of SBS, mice
undergo massive resection leaving only 25% of the original small intestine intact 18. Following
resection, the remaining small intestines experience significant muscular and mucosal
hyperplasia. It has since been shown that this response is caused by GLP-2, an enteric hormone
that is released after injury to the small intestines 19. GLP-2 is thought to promote intestinal
adaptation after injury in order to allow the healthy mucosa to increase its ability to absorb
nutrients to make up for any lost or damaged tissue. Similar to the mouse model of SBS, rat
models of jejuno-ileal bypass 20 and biliopancreatic diversion 21 have been found to experience
muscular and mucosal hyperplasia in the intestines following surgery. In actual RYGB, it has
been shown that there is an increase in circulating levels of GLP-2, as well as an increase in
crypt depth and villus height 22. Despite this, no studies have been done characterizing the effect
of the adaptive response on enteroendocrine cells within the intestinal mucosa. We aim to
investigate whether or not the adaptive response occurs in our model of RYGB, and if it does,
how it affects enteroendocrine cell populations.
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2.2 Methods
2.2.1 Animals
Male Sprague-Dawley rats weighing ~200 g (Harlan Industries, Indianapolis, IN) were
housed individually in wire-mesh cages at a constant temperature of 21-23º C with a 12h lightdark cycle (lights on at 07:00, off at 19:00). Food and water were provided ad libitum unless
otherwise indicated. Animals were made obese by putting them on a two-choice diet for 14-16
weeks consisting of normal laboratory chow (Kcal%: Carb, 58; Fat, 13.5; Prot, 28.5, # 5001,
Purina LabDiet, Richmond IN ) and high-fat diet (sweet HF diet; Kcal%: Carb, 20; Fat, 60; Prot,
20, D12451, Research Diets, New Brunswick, NJ), with each of the diets containing sufficient
minerals and vitamins. Small amounts of liquid Ensure diet (Kcal%: Carb, 64; Fat, 21.6; Prot,
14.4, Abbott Laboratories, Columbus, OH) was also provided before surgery. They were then
randomly assigned to either RYGB or sham surgery. After surgery, only liquid Ensure was
provided as a source of food for the first 10 days, before giving back increasing amounts of
regular chow and HF diet. A lean control group without surgery was placed on a regular chow
diet throughout the experiment.
All protocols involved in this study were approved by the Institutional Animal Care and Use
Committee at the Pennington Biomedical Research Center in accordance with guidelines
established by the National Institutes of Health.

2.2.2 Roux-en-Y gastric bypass and sham surgery
Details of the RYGB surgical procedure have been reported earlier 23,24(11, 28). Briefly,
the procedure resulted in a gastric pouch of about 20% of the total gastric volume, connected to a
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15 cm-long Roux limb, a 25 cm-long common limb, and a roughly 40 cm-long biliopancreatic
limb.
Sham-surgery consisted of the same procedure as for RYGB, except that the transected
jejunum was re-anastomosed, one small incision in the jejunum 25 cm from ileocecal valve and
one in the gastric fundus were sutured closed, and the cutting stapler was laid over the stomach
without firing. Thus, a similar amount of surgical trauma was inflicted, but the normal flow of
nutrients was preserved in sham-operated rats. To overcome potential deficits in iron absorption
and development of anemia, rats were administered a macromolecular dextran-iron complex
(Iron Dextran injectable, catalog # 93963, 5 mg, s.c.; Town and Country, Ashland, OH) once a
week for the first two weeks after RYGB surgery. Additional doses were administered to
individual anemic animals if indicated.

2.2.3 Tissue preparation and Immunohistochemistry
Ten to eleven months after surgery, rats were euthanized after overnight food deprivation, and
the gastrointestinal tract was harvested. This time point after surgery was chosen because the
animals were involved in behavioral tests and hormone measurements, the results of which were
reported previously 23,24. Furthermore, this extended postsurgical period allowed us to assure the
long-term effectiveness of the procedure on body weight and adiposity, and most likely captured
the final state of adaptive changes. Half the tissue samples from each location were immersionfixed in 10% buffered formalin for later immunohistochemical processing, and the other half was
rapidly frozen in liquid nitrogen for later quantitative PCR or Western immuno-blotting. After
washing in saline, the fixed samples were soaked in 18% sucrose, 0.05% sodium azide in 0.1M
phosphate buffered saline (PBS) solution for cryoprotection. Tissue samples were then frozen
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and 30 micron-thick sections were cut in a cryostat and separated into five series. For immediate
processing, sections were held in PBS (+4oC), whereas for long-term storage (–20oC), a
cryoprotectant solution (50% PBS, 30% ethylene glycol, 20% glycerol) was used. Free-floating
sections were pre-treated with 0.5% sodium borohydride in PBS to minimize aldehyde crosslinking of the fixative and treated with a blocking solution containing 5% normal goat or donkey
serum in PBS containing 0.5% Triton X-100 (PBST). Appropriate washing in PBS followed all
incubations. The sections were incubated in primary antibody (CCK-antibody 1: 400, raised in
rabbit against synthetic CCK-39, Peninsula, Belmont, CA; GLP-1 mouse monoclonal antibody
1:5000, ImmunDiagnostik, Bensheim, Germany, distributed by ALPCO, Windham, NH; rabbit
anti-neurotensin 1:5000, ImmunoStar, Hudson, WI; 5-HT antibody 1:50’000, rabbit antiserotonin, ImmunoStar, Hudson, WI; goat anti-ghrelin 1:1000, Santa Cruz Biotechnology, Santa
Cruz, CA.) diluted in PBST containing 0.1% gelatin and 0.05% sodium azide, overnight at room
temperature, or at 40C for 20h, under gentle agitation by an orbital shaker. After thoroughly
rinsing in PBS, they were reacted with Cy-3-conjugated anti-rabbit, anti-goat, or anti-mouse IgG
secondary antibody (Jackson Immuno Research, West Grove, PA) before mounting and cover
slipping in an aqueous medium. Staining was completely absent in control experiments with
omission of the primary antibody or, for CCK-39, with incubation in primary antibody that had
been preabsorbed by adding 10 mol sulfated CCK-8 for 4h at room temperature. Further,
manufacturer-supplied data indicate that this antibody is more selective for CCK than antibodies
raised against CCK-8, since it is not inhibited by preabsorption in 10 nmol gastrin I, Tetrin, and
Somatostatin-14.
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2.2.4 Immunohistochemical Analysis
Whole sections were mounted onto Superfrost glass slides using Fluoromount G
(Southern Biotechnology, Birmingham, AL) as the mounting medium. Sections were viewed
using a Zeiss Axioplan fluorescence microscope. Counts were performed visually. Cells that
were immunoreactive but did not have clear enteroendocrine cell morphology, such as 5-HTpositive mast cells, were not counted. Counts were based on averages from 2-4 intestinal crosssections from each limb for each animal. For Ghrelin cell counts, the average of 7 sections from
corpus of the stomach was used.

2.2.5 Morphological measurements
Tissue measurements were performed visually using a Zeiss Axioplan fluorescence
microscope in conjunction with a 10x10 ocular grid at 20x magnification. A micro slide ruler
was used to determine that the 10x10 grid had a 50 micrometer resolution. For sampling
purposes, two sections were chosen from each limb of each animal. Measurements of tissue
thickness were taken at four points on each section for the longitudinal muscle, circular muscle,
sub-mucosa, and mucosa (combined thickness of crypts and villi). If four measurements could
not be taken on each of the two sections selected, two additional sections were chosen for that
particular limb and counted to provide additional measurements. The average thickness of the
tissue was calculated for each limb of each animal, and these averages were used for statistical
analysis.
For measurements of total and mucosal cross-sectional areas, darkfield images were
generated in a Leitz microscope with a 1x macro lens and areas determined using the paper
weighing method. Average cross-sectional areas were calculated from at least 3 representative

28

sections per rat and limb. Enteroendocrine cell densities were calculated as number of cells per
mm2.

2.2.6 Statistical analysis
Morphological measurements and enteroendocrine cell counts were analyzed by two-way
ANOVA with gut location as within subject factor and surgical group as between subject factor,
followed by Bonferroni-adjusted multiple comparisons. Ghrelin cell counts were analyzed by
one-way analysis of variance. All data were expressed as mean ± SEM.

2.3 Results
2.3.1 RYGB-induces hypertrophy of the Roux and common limbs
The diameter of the Roux and common limbs, but not the biliopancreatic limb, were greatly
increased compared to the corresponding gut segments of sham-operated rats (Figure 2.1).
Similarly, the total and mucosal surface areas of the cross-sectioned Roux and common limbs
were significantly increased (Figure 2.2). Both the longitudinal and circular muscle layers of the
Roux limb and the circular muscle layer in the common limb were about 2-fold thicker in RYGB
rats compared with both other groups (Figure 2.3). No differences in the thickness of the external
muscle layers were observed in the biliopancreatic limb. The total mucosa (crypt plus villous
height) in the Roux and common limbs was also significantly thicker in RYGB rats compared to
both control groups. No significant differences were observed for the submucosa thickness.
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Figure 2.1 Representative dark field images of cross-sections of the biliopancreatic (a, d)
Roux (b, e), and common (c, f) limbs or their corresponding gut segments of rats at 10-11
months after RYGB (a-c) or sham surgery (d-f), showing hypertrophy of the Roux and
common limbs but not the biliopancreatic limb. Surface areas in mm2 of the representative
cross-sectioned segments are shown in the left bottom corner of each panel. Scale bar in f,
1.0 mm.

Figure 2.2 Average total and mucosal cross-sectional areas of the Roux and common limbs
from rats at 10-11 months after Roux-en-Y gastric bypass surgery (n = 4) or sham-operation
(n = 4). * p < 0.05 compared with both chow-fed controls and sham-operated rats, based on
t-tests.
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Figure 2.3 Thickness of intestinal wall layers in the biliopancreatic, Roux, and common
limbs (or their equivalent) in non-operated, chow-fed lean rats (n = 4), sham-operated, highfat fed obese rats (n = 4), and Roux-en-Y gastric bypass rats (n =4), 10-11 months after
surgery. * p < 0.05 compared with both chow-fed controls and sham-operated rats, based on
ANOVA followed by Bonferroni-adjusted multiple comparisons.

2.3.2 Increased number, but not density, of enteroendocrine cells in the Roux and common limbs
ANOVA yielded significant effects of surgical treatment (F[2,24] = 20.7, p< 0.001) and gut
location (F[2,24] = 9.9, p< 0.001), as well as a significant interaction (F[4,24] = 7.6, p< 0.001).
As expected, in chow fed lean control rats, almost twice as many CCK-IR cells were expressed
in the upper small intestine (the area corresponding to the biliopancreatic limb), compared with
the lower small intestine (the area corresponding to the Roux and common limbs). (Figure 2.4,
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Figure 2.4 Examples of CCK (a,b), GLP-1 (c,d), and 5-HT (e,f), immunoreactive
enteroendocine cells in the Roux limb, neurotensin immunoreactive cells in the common
limb (g,h), and ghrelin immunoreactive cells in the gastric antrum of the remnant stomach
(i), 10-11 months after Roux-en-Y gastric bypass surgery. Note that different
magnifications are used to emphasize shape and distribution of enteroendocrine cells in villi
and crypts. Abbreviations: cm, circular muscle; sm, submucosa. Scale bars, 100 µm for all
panels.

Figure 2.5). These numbers were not significantly different in high fat diet-induced obese rats
with sham operation. However, in RYGB rats, the numbers of CCK-IR cells were significantly
higher in the Roux limb (t = 3.5, p< 0.005) and common limbs (t = 7.4, p< 0.001), but not in the
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biliopancreatic limb. Compared to sham-operated rats, the increase was about 2-fold in the Roux
limb and about 3-fold in the common limb.
In the Roux limb, the density of CCK-cells was not significantly different after RYGB,
compared with sham-operated rats (Figure 2.7), because the cross-sectional area of the mucosa
was also increased about 3-fold (Figure 2.2). In the common limb, the density of CCK-cells was
significantly higher after RYGB compared with sham-operated rats (Figure 2.7), as the increased
cell number was not fully compensated for by increased mucosal area.
ANOVA yielded significant effects of surgical treatment (F[2,24] = 34.4, p< 0.001) and gut
location (F[2,24] = 23.2, p< 0.001), as well as a significant interaction (F[4,24] = 8.2, p< 0.001).
There was only a slight and non-significant gradient in the expression of GLP-1-IR cells across
the small intestine in chow-fed, lean control rats, with the proximal part (biliopancreatic and
Roux limbs) expressing about 150 cells per section and the distal part (common limb) expressing
about 200 cells per section (Figure 2.4, Figure 2.5). There were no significant differences
between chow-fed lean and sham-operated, high fat-fed obese rats. In contrast, after RYGB,
there was a significant (t = 4.2, p< 0.001) 2-fold increase of GLP-1-IR cell expression in the
Roux limb, and a significant (t = 8.4, p< 0.001) 2.5-fold increase in the common limb, compared
to sham-operated rats. Most of the CCK-IR and GLP-1-IR cells were found in the crypt area, and
there were no obvious differences in this distribution pattern between the three groups. The
density of GLP-1 cells was, however, not significantly different after RYGB, compared with
sham-operated rats (Figure 2.7).
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Figure 2.5 Number of CCK (a) and GLP-1 (b) immunoreactive cells in the biliopancreatic,
Roux, and common limbs (or their equivalent) in non-operated, chow-fed lean rats (n = 3),
sham-operated, high-fat fed obese rats (n = 4), and Roux-en-Y gastric bypass rats (n =4),
10-11 months after surgery. * p < 0.05 compared with both chow-fed controls and shamoperated rats, based on ANOVA followed by Bonferroni-adjusted multiple comparisons.

The 5-HT antibody stained both enteroendocrine and mast cells, but only enteroendocrine
cells were counted based on their distinctive location in the epithelium and elongated shape
(Figure 2.4). ANOVA yielded significant effects of surgical treatment (F[2,26] = 23.5, p< 0.001)
and gut location (F[2,26] = 13.7, p< 0.001), as well as a significant interaction (F[4,26] = 10.5,
p< 0.001). In chow-fed control rats we found similar numbers of 5-HT-IR enteroendocrine cells
per cross-section at the locations corresponding to the three surgical limbs, and sham surgery did
not result in significant changes (Figure 2.6). After RYGB, however, there was a significant
increase in 5-HT-IR enteroendocrine cells in the Roux (t = 7.26, p<0.001) and common limb (t =
4.0, p<0.01), but not in the bypassed biliopancreatic limb. The density of 5-HT-cells was not
significantly different after RYGB compared to sham-operated rats (Figure 2.7).
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Figure 2.6 Number of 5-HT (a) and neurotensin (b) immunoreactive cells in the
biliopancreatic, Roux, and common limbs (or their equivalent) in non-operated, chow-fed
lean rats (n = 4), sham-operated, high-fat fed obese rats (n = 4), and Roux-en-Y gastric
bypass rats (n =4), 10-11 months after surgery. * p < 0.05 compared with both chow-fed
controls and sham-operated rats, based on ANOVA followed by Bonferroni-adjusted
multiple comparisons.

ANOVA yielded significant effects of surgical treatment (F[2,23] = 21.7, p< 0.001) and gut
location (F[2,23] = 81.4, p< 0.001), as well as a significant interaction (F[4,23] = 6.8, p< 0.001).
In chow-fed control rats, there was a proximal-to-distal gradient in the number of neurotensin-IR
enteroendocrine cells, with fewer cells at the location corresponding to the biliopancreatic limb
and more in the mid-jejunum (corresponding to the Roux limb) and the distal jejunum
(corresponding to the common limb) (Figure 2.4, Figure 2.6). Furthermore, as determined for
the biliopancreatic limb and unlike the other types of cells, the majority of neurotensin-IR cells
were located in the villi (29 ± 6 cells) and a minority in the crypts (13 ± 1 cells; p < 0.05). The
number of cells was not much different in sham-operated rats, but in RYGB rats, there were
significantly more neurotensin-IR cells in the Roux-limb (t = 5.8, p<0.001) and in the common
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limb (t = 6.1, p<0.001), but not in the biliopancreatic limb. However, because the cross-sectional
areas of the Roux and common limb mucosa was increased about 2-3-fold (Figure 2.2), the
density of neurotensin cells was significantly decreased after RYGB, compared with shamoperated rats (Figure 2.7).

Figure 2.7 Enteroendocrine cell densities in the Roux and common limbs of rats at 10-11
months after Roux-en-Y gastric bypass (n = 4) or sham surgery (n =4). * p < 0.05 compared
with sham-operated rats, based on ANOVA followed by Bonferroni-adjusted multiple
comparisons.

There were very few ghrelin-IR cells in the small intestines and no obvious differences
between the treatment groups (data not shown). In the corpus of the bypassed stomach, we found
slightly more ghrelin-IR cells in RYGB rats compared to sham-operated rats and chow-fed
control rats, but the difference was not statistically significant (p = 0.096) (Figure 2.3, Figure
2.8).
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Figure 2.8 Number of ghrelin-immunoreactive cells in the gastric mucosa of non-operated,
chow-fed lean rats (n = 4), sham-operated, high-fat fed obese rats (n = 4), and Roux-en-Y
gastric bypass rats (n =4), 10-11 months after surgery.

2.4 Discussion
The mechanisms responsible for an increase in the secretion profile of lower gut
hormones such as GLP-1, PYY, CCK, neurotensin, and 5-HT following RYGB are not well
understood. It is not clear whether this is caused by an increase in releasing stimuli, increased
secretory efficiency, increased number of hormone releasing cells, reduced degradation of
hormones in circulation, or some other combination of factors. Here, we provide evidence that
there is a significant increase in the number of enteroendocrine cells in the Roux and common
limbs after RYGB. This proliferation appears to not be a response specific to enteroendocrine
cells, but instead is due to generalized hyperplasia of the intestinal mucosa. This is evidenced by
the fact that, apart from CCK, there is no significant increase in the density of enteroendocrine
cells in the mucosa, implying that other mucosal cells are also proliferating at approximately the
same rate. An increase in the number of hormone releasing cells may be responsible for the
increase in hormone secretion observed after RYGB. However, our data does not provide
causative evidence for this claim, and does not rule out other possible mechanisms.
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Our findings both support and extend data reported by other labs showing mucosal
hyperplasia after various intestinal surgeries. Previously, Nadreau et al 21 showed that intestinal
adaptation occurs as early as 7 weeks after biliopancreatic diversion, a procedure very similar to
RYGB. Secretory studies have also shown that there is an increase in plasma concentrations of
GLP-2 and the growth factor IGF-1 as early as 2 weeks after RYGB 22. These reports, along with
our data showing significant hyperplasia at 10-11 months post surgery, support the idea that
intestinal adaptation happens quickly after surgery and is maintained indefinitely.
We have also extended our understanding of intestinal adaptation by showing that despite
a global increase in the circulating levels of GLP-2 after RYGB, only the Roux and common
limbs experienced significant levels of tissue growth. It has been previously suggested that
exposure of the lower small intestine to nutrients is not required for adaptive hyperplasia to occur
25

. However, most studies to this point have used animal models with a continuous digestive tract

to investigate this phenomenon, and therefore have not reported a differential response in
intestinal hyperplasia in the presence of high circulating GLP-2. Our data shows that despite
systemic increases in circulating GLP-2, adaptive hyperplasia still only occurs in the intestinal
limbs that are exposed to nutrients. One possible explanation for this phenomenon involves the
observation that, in the absence of exposure to enteral nutrients, the intestinal mucosa
experiences atrophy 26. High circulating GLP-2 following RYGB, which induces hyperplasia,
may be balancing against the expected atrophy of the biliopancreatic limb, resulting in no net
change in the mucosa. In any case, we show clear evidence that the presence of enteral nutrients
plays a key role in the adaptive response of the intestines.
Our study paves the way for new experiments looking into enteric hormones as a major
mediator of the beneficial effects of RYGB. GLP-1 and PYY are the hormones that have been
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most strongly linked to weight loss and improved glucose homeostasis after RYGB. Both act as
anorexigenic hormones 27,28, and GLP-1 has the additional benefit of acting as an incretin
hormone to help normalize blood glucose levels 29. One study using PYY-deficient mice found
that PYY was necessary for RYGB to lower body weight, however their observation period was
only 10 days after surgery and therefore may not give a complete picture of PYY’s role in
RYGB 30. Another study blocked GLP-1 receptor activity by systemically infusing the GLP-1
receptor antagonist Exendin(9-39) for 5-10 days after surgery 31. They found that this partially
prevented RYGB associated anorexia, but did not significantly affect weight loss. Again, this
study only looked at the early postoperative period and therefore does not give a clear picture of
the role of GLP-1 in RYGB mediated weight loss. Other gut hormones, such as CCK, 5-HT, and
neurotensin have been even less well studied.
More in depth long term experiments will be needed to determine whether or not GLP-1,
PYY, or any of the other enteric hormones are required to mediate the beneficial effects of
RYGB. However, experiments using either antagonist infusion or receptor knockouts are
generally limited to looking at a single hormone at a time. This is due to the fact that long term
infusion of multiple receptor antagonists quickly becomes prohibitively expensive, and
generation of double, triple, or quadruple receptor knockout models is equally difficult. With our
observation that proliferation of enteroendocrine cells is a likely mechanism leading to the
increase in circulating anorexigenic hormones after RYGB, it may be possible to create a rodent
model that does not attempt to interfere with individual hormones and their receptors, but instead
attempts to interfere with the adaptive hyperplasia of the small intestine. This would prevent
RYGB from having any significant effect on circulating levels of these hormones without
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affecting their activity anywhere else in the body. It would also allow for the investigation of the
enteric hormones as a group rather than trying to interfere with them each individually.
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CHAPTER 3: ADAPTIVE HYPERPLASIA AND REPROGRAMMING OF INTESTINAL
GLUCOSE METABOLISM ARE NOT PRESENT AFTER VERTICAL SLEEVE
GASTRECTOMY IN RATS
3.1 Introduction
In the months following the experiment outlined in the previous chapter, a number of
studies were published investigating the role of both GLP-1 and PYY in mediating the effects of
RYGB on obese rats and mice. One study performed by our lab found that pharmacological
inhibition of central GLP-1 signaling using the GLP-1r antagonist exendin(9-39) reversed the
effects of RYGB and caused rats to increase their food intake and return to pre-surgical obese
levels 1. However, this effect was even more pronounced in sham control animals, and is
therefore unlikely to be a unique mechanism through which RYGB acts. In the same study we
found that central infusion of the Y2-receptor antagonist BIIE0246 had no significant effect on
food intake in either the RYGB or control groups receiving sham surgery. Other studies
performed around the same time showed that GLP-1 signaling did not seem to be necessary for
the effects of RYGB or VSG surgeries 2,3. Surprisingly, no evidence to date has been able to
support the idea that any single gastric hormone plays a significant role in mediating the weight
loss effects of RYGB. It would appear that, except for the possibility of a complex interaction
resulting from altered secretion profiles of multiple gastric hormones simultaneously, elevated
levels of these hormones do not play a causative role in weight loss after RYGB. This also cast
doubt on the mechanistic role of adaptive hyperplasia, which was implicated in the increased
release of gastric hormones following RYGB in the previous chapter.

This chapter previously appeared as Mumphrey, M. B., Hao, Z., Townsend, R. L., Patterson, L.
M. & Berthoud, H.-R. Sleeve Gastrectomy Does Not Cause Hypertrophy and Reprogramming of
Intestinal Glucose Metabolism in Rats. Obes. Surg. (2015). It is reprinted by permission of
Springer.
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In the wake of these studies, a seminal paper was published describing another
mechanism through which adaptive hyperplasia could mediate the beneficial effects of RYGB 4.
Saeidi et al found that intestinal hyperplasia after RYGB lead to massively increased glucose
uptake by the intestines, as well as significant reprogramming of intestinal glucose metabolism .
They found that key proteins in the glycolytic pathway were upregulated, and that there was a
decrease in the amount of glucose shunted towards the tricarboxylic acid cycle, suggesting that
the intestines were being switched to a more anabolic metabolic profile. They also found that
total glucose disposal via the intestines was doubled, causing the intestines to become the largest
glucose sink in the body, with glucose disposal per gram of tissue almost reaching the same level
as the brain. Their findings support the idea that intestinal hyperplasia following RYGB could
still be responsible for the improvements in body weight and glucose homeostasis seen after the
surgery by altering the way that glucose is metabolised after consuming a meal.
Here, we further investigated the importance of intestinal hyperplasia following bariatric
surgery by characterizing the response after VSG, a similar procedure. VSG has nearly identical
effects on both body weight and glucose homeostasis when compared to RYGB 5,6, and is
becoming a popular alternative to RYGB due to its less invasive nature. Although there are
physical differences between RYGB and VSG surgeries, the effects on obese subjects are so
remarkably similar that it is generally thought that the two work through the same mechanism
and are interchangeable when generating mouse models to study 7,8. We hypothesized that if the
two surgeries do share a common mechanism, and if that mechanism requires intestinal
adaptation after RYGB, then we should observe the same response after VSG.
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3.2 Methods
3.2.1 Animals and diets
Male Sprague-Dawley rats weighing ~200 g (Harlan Industries, Indianapolis, IN) were
housed individually in wire-mesh cages at a constant temperature of 21-23º C with a 12h lightdark cycle (lights on at 07:00, off at 19:00). Food and water were provided ad libitum unless
otherwise indicated. Animals were made obese by putting them on a two-choice diet for 14-16
weeks consisting of normal laboratory chow (Kcal%: Carb, 58; Fat, 13.5; Prot, 28.5, # 5001,
Purina LabDiet, Richmond IN ) and high-fat diet (Kcal%: Carb, 35; Fat, 45; Prot, 20; D12451,
Research Diets, New Brunswick, NJ), with each of the diets containing sufficient vitamins and
minerals. They were then randomly assigned to either VSG or sham surgery. A lean control
group without surgery was placed on a regular chow diet throughout the experiment.
All protocols involved in this study were approved by the Institutional Animal Care and Use
Committee at the Pennington Biomedical Research Center in accordance with guidelines
established by the National Institutes of Health.

3.2.2 Surgery and postoperative care
To remove all solid food particles from the stomach, rats undergoing VSG were fed liquid
Ensure (Kcal%: Carb, 64; Fat, 21.6; Prot, 14.4, Abbott Laboratories, Columbus, OH) for 3-5
days. Ensure was removed the night before surgery. Rats were anesthetized with isoflurane and
administered atropine (1 mg/kg, s.c.). After laparotomy and removal of the gastric omentum, the
stomach was placed on the open tongue of a cutting stapler (Model ATW35 with two straight
triple-staple lines; Ethicon, Ithaca, NY), making sure that most of the fundus was below the
staple line. The tongues of the stapler were then slowly closed starting from fundus to antrum
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and the knife activated, resulting in the removal of about 80% of the total stomach volume. Any
epiploic blood vessels not included in the staple line were ligated and the severed portion of the
stomach was removed. The rest of the stomach was put back in place before suturing muscle and
skin separately. Sham surgery consisted of laparotomy and removal of the gastric omentum.
RYGB was carried out according to a protocol described in detail earlier 9. Briefly, a gastric
pouch of about 20 % of the total gastric volume was anastomosed with a 15-cm-long Roux limb
and the 25-cm-long common limb with a roughly 40-cm-long biliopancreatic limb. Sham surgery
consisted of the same basic procedure as for RYGB, except that the transected jejunum was
reanastomosed and a small incision in the jejunum 25 cm from ileocecal valve and one in the
gastric fundus were sutured closed.
After surgery, only liquid Ensure was provided for the first 10 days, before giving back
increasing amounts of regular chow and HF diet.

3.2.3 Measurement of body weight, body composition, and food intake
Body weight was monitored daily for the first two weeks, and then was recorded weekly.
Body composition was measured before introduction of the high-fat diet (16 weeks before
surgery), and monthly after surgery, by using a Minispec LF 90 NMR Analyzer (Bruker
Corporation, The Woodlands, TX). This method uses whole body magnetic resonance
relaxometry in unanesthetized rodents with excellent linearity and reproducibility 10.

3.2.4 Immunohistochemical and morphometric analysis
3 months after surgery, rats were euthanized after overnight food deprivation, and the
gastrointestinal tract was harvested. Half the tissue samples from each location were immersion-
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fixed in 10% buffered formalin for later immunohistochemical processing, and the other half was
rapidly frozen in liquid nitrogen for later extraction of protein. Immunohistochemical processing
and analysis was carried out as previously reported 9. Briefly, GLP-1 mouse monoclonal
antibody 1:5000 (ImmunDiagnostik, Bensheim, Germany, distributed by ALPCO, Windham,
NH) was used as primary antibody. Sections were viewed using a Zeiss Axioplan fluorescence
microscope. GLP-1 immunoreactive enteroendocrine cells were counted only if the nucleus was
clearly visible. Counts were averages from 2-4 intestinal cross-sections from each limb for each
animal.
Measurements of cross-sectional areas and mucosal thickness have been described earlier 9.
Briefly, average thickness of the mucosa (combined thickness of crypts and villi) was calculated
for each limb of each animal, and these averages were used for statistical analysis.
Cross-sectional areas were measured based on darkfield images generated in a Leitz
microscope with a 1x macro lens and image analysis software (ImageJ, NIH, Bethesda, MD).
Average cross-sectional areas were calculated from at least 3 representative sections per rat and
limb.

3.2.5 Western blotting
Frozen intestinal tissues were crushed to powder using liquid nitrogen cooled mortar and
pestles. Frozen powder was transferred to conical tubes and 1 ml of ice cold T-PER Tissue
Protein Extraction Reagent (Thermo Fisher Scientific Inc., Waltham, MA, Cat # 78510)
containing 1X Halt Protease Inhibitor Cocktail (complete EDTA-free, Thermo Fisher Sceintific
Inc., Cat # 87785) was added. Samples were homogenized for 30 s on ice, and then sonicated
using a Branson Sonifier S-450 Digital Ultrasonic Cell Disruptor/Homogenizer (Branson
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Ultrasonics Americas, Danbury, CT). Samples were centrifuged at 12,000 rpm for 20 min.
Protein concentration of each lysate was determined using BCA Protein Assay Kit (Thermo
Fisher). Protein lysates were heated at 950 C for 5 min with Laemmli buffer and separated by
polyacrylamide gel electrophoresis through 12% SDS gels. Proteins were transferred to PVDF
membranes (Bio-Rad Laboratories, Inc., Hercules, CA, Cat. # 162-0177) at 100V for 70 min at
40 C, using a wet transfer system (Mini Trans-Blot, Bio-Rad Laboratories, Inc.). Membranes
were blocked in 5% milk dissolved in PBS-T (1X PBS + 0.1% Tween20) for 45 min at room
temperature. Primary antibodies were diluted in 5% milk or 5% bovine serum albumin in PBS-T
according to manufacturer’s recommendations. Anti-beta 2 Microglobulin antibody (B2M, rabbit
monoclonal [EP2978Y], ab75835, Abcam, Cambridge, MA) was used at 1:20,000 dilution.
Hexokinase II antibody (rabbit monoclonal [C64G5], Cat. # 2867, Cell Signaling Technology,
Danvers, MA) was used at 1:1,000 dilution. Blots were incubated with primary antibodies
overnight at 40 C. After washing with PBS-T, blots were incubated with goat anti-rabbit IgG
HRP-linked (Cat # 7074, Cell Signaling Technology) in 5% milk dissolved in PBS-T for 1 h at
room temperature. Membranes were developed using Western Lightning Plus-ECL, Enhanced
Chemiluminescence Substrate (PerkinElmer Inc., Waltham, MA, Cat # NEL104001EA).

3.2.6 Statistical analysis
Body weight, body composition, and food intake across time were analyzed by two-way
repeated measures ANOVA, followed by Bonferroni’s post-hoc multiple comparison test. Crosssectional area, mucosal thickness, and the number of GLP-1 -IR cells per section were analyzed
by two-way ANOVA, and hexokinase II expression by t-test.
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3.3 Results
3.3.1 VSG in high-fat obese rats reduces body weight and fat mass to levels of chow-fed controls
Exposure to the high-fat diet for 14 weeks resulted in significantly increased body weight
(Figure 3.1a) and fat mass (Figure 3.1b) compared with age-matched chow-fed controls.
Subsequent VSG in the obese rats led to a rapid decrease, followed by a slow and steady regain
of body weight, whereas sham surgery resulted in only a small transient decrease (Figure 3.1a).
At the end of the 3-month observation period, VSG rats weighed 521 ± 11 g, significantly less
than sham-operated (~609 ± 11 g), but not significantly different from chow-fed control rats (537
± 16 g). Body weight loss at 54 days after VSG was almost entirely due to fat mass loss, with
only a small loss of lean mass (Figure 3.1b,e). Body weight gain in sham-operated rats was due

Figure 3.1 Effect of VSG in diet-induced obese rats on body weight and composition. (a) Rats
exposed to a two-choice high/low-fat diet were either subjected to VSG (closed circles, n=8) or
sham surgery (open circles, n= 9) and were compared to rats exposed to regular low-fat chow
(open triangles, n=4). Body weight was monitored before and for 3 months after surgery.
*p<0.05, VSG vs. sham; ^p<0.05, VSG and sham vs. chow. (b, c) Total fat mass and relative fat
mass (adiposity) measured by NMR whole body imaging, 80 days after surgery. (d) Epididymal
and retroperitoneal fat pad weights measured at termination, 90 days after surgery. (e) Lean mass
at 80 days after surgery. Bars that do not share the same letters are significantly different from
each other (based on ANOVA followed by Bonferroni-corrected multiple comparisons)
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to both fat mass and lean mass gain (Figure 3.1b,e). Just before the end of the 3-month
observation period, total fat mass and percent fat mass (adiposity) were significantly lower in
VSG rats compared with sham-operated rats, but not significantly different from chow-fed
controls (Figure 3.1b,c). Both epididymal and retroperitoneal fat pads weighed significantly less
in VSG compared with sham-operated rats and were only slightly higher than in chow-fed
controls (Figure 3.1d). Lean mass was slightly, but not significantly, lower 80 days after VSG
compared with both sham-operated and chow controls (Figure 3.1e).

3.3.2 VSG transiently reduces energy intake
Before surgery, high-fat-fed rats ingested slightly (~10 %) but significantly more calories than
chow-fed controls (Figure 3.2). VSG initially reduced total energy intake but, it returned to presurgical levels after about 20 days and remained at this level for the rest of the study. Sham
operation reduced energy intake only briefly, followed by an overshoot and subsequent
stabilization at a level about 15% higher than VSG animals. Average daily energy intake in VSG
rats was significantly reduced by about 40% during the first month and by about 15% during the
second and third month, compared to sham-operated rats (Figure 3.2 inset).

3.3.3 VSG does not increase cross-sectional area of small intestine and thickness of mucosa
The small intestine of VSG rats does not show the hypertrophic response seen after RYGB
(Figure 3.3). Cross-sectional areas (Figure 3.3a, b) and mucosal thickness (Figure 3.3c) of
duodenum, jejunum and ileum, were similar in VSG and sham-operated rats. In contrast, crosssectional areas and mucosal thickness for the corresponding intestinal locations (Roux and
common limbs) are significantly larger after RYGB.

50

Figure 3.2 Effect of VSG in diet-induced obese rats on food intake. Total intake of high and low
fat offered as two-choice diet monitored before and 3 months after surgery in rats with VSG
(closed circles, n=8) or sham surgery (open circles, n=9), compared with non-surgical rats fed
low-fat regular chow (open triangles, n=4). *p<0.05, VSG vs. sham; # p<0.05, VSG vs. chow;
^p<0.05, VSG and sham vs. chow. The inset shows average daily total (from high- and low-fat
diet) food intake during the first, second, and third month post-surgery. Bars that do not share the
same letters are significantly different from each other (based on ANOVA followed by
Bonferroni-corrected multiple comparisons)

Figure 3.3 Effect of VSG and RYGB in rats on cross-sectional area and mucosal thickness at
three locations of the small intestine. (a) Representative histological cross sections of the
duodenum, jejunum, and ileum after VSG (n= 6) or sham surgery (n=4) and of the corresponding
biliopancreatic (BP), Roux (Rx), and common (CM) limbs after Roux-en-Y gastric bypass (n=4).
Note the absence of any enlargement of small intestinal diameter and surface area after VSG.
Scale bar=1 mm. (b) Quantitative assessment of cross-sectional area of corresponding intestinal
segments after VSG and RYGB and their respective sham surgeries. (c) Mucosal thickness is not
significantly different between VSG and sham rats, but as reported earlier 9 is significantly
higher after RYGB compared to all other groups.*p<0.01, RYGB vs. sham
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3.3.4 VSG does not change number of GLP-1 immunoreactive L-cells
Immunohistochemical staining of GLP-1-producing L-cells showed no difference of
number and distribution between VSG and sham-operated rats (Figure 3.4). As expected, the
number of L-cells per section was much lower in the duodenum than in the jejunum and ileum.
This contrasts with our earlier data 9 and observations by others 11, showing more than doubling
of the number of L-cells and other enteroendocrine cells in the Roux and common limbs but not
the biliopancreatic limb after gastric bypass.

Figure 3.4 Effect of VSG on number of GLP-1 immunoreactive enteroendocrine cells at three
locations of the small intestine. (a) Representative images of GLP-1 cells in the jejunal mucosa
after VSG and sham surgery. Scale bars=50 μm. (b) Quantitative analysis of the number of GLP1 cells per section in the duodenum, jejunum, and ileum of rats after VSG (n=6) and sham
surgery (n=7)

3.3.5 RYGB, but not VSG increases hexokinase-II protein expression in small intestine
Protein expression of hexokinase II was significantly elevated in the Roux limb of rats 10
months after RYGB (Figure 3.5b), confirming earlier observations by Saeidi et al. 4. However,
expression of this key glycolytic enzyme was not increased in the upper small intestine 3 months
after VSG (Figure 3.5a).
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3.4 Discussion
Adaptive hyperplasia and reprogramming of intestinal glucose metabolism has been
identified as a potential mechanism through which RYGB acts to lower body weight and
improve glucose homeostasis in obese patients 4. Studies have shown that these improvements
are almost identical in both rodents and humans after VSG 5,6. Because both surgeries have such
similar outcomes, it is often hypothesized that they share a common mechanism of action 7,8.
Supporting this idea is the observation that after VSG there is a similar increase in circulating
levels of GLP-2, the hormone responsible for intestinal hyperplasia following RYGB 12. It is
therefore expected that VSG should cause adaptive hyperplasia of the intestines just like RYGB.

Figure 3.5 Effect of VSG (a) or RYGB (b) in rats on protein expression of hexokinase II (HKII)
in the jejunum and corresponding Roux limb. Original Western blot images were generated from
one single gel for VSG and it’s sham control (a), and one single gel for RYGB and it’s sham
control (b), but have been cropped and condensed for clarity. Quantitative densitometric analysis
is shown on the right for VSG (n=6) and sham VSG (n= 6) as well as for RYGB (n=5) and sham
RYGB (n=5). There was no significant difference between VSG and sham-operated rats, but
significantly increased hexokinase II after RYGB compared with sham. *p<0.01, RYGB vs.
sham. B2M beta-2-microglobulin
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Here, we show that there is no intestinal hyperplasia in rats after VSG. This is especially
surprising considering the increased circulating levels of GLP-2 observed after the surgery 12.
However, growth of the intestinal mucosa is due to the combined effect of an increase in cellular
proliferation in the crypts of lieberkuhn and a decrease in apoptosis in the villi 13. It was therefore
possible that after VSG there was a reprogramming of intestinal tissue to an anabolic state, but a
proportional increase in the rate of apoptosis in the villi leading to no net tissue growth. For this
reason we also investigated the change in the expression of hexokinase-II, an important enzyme
in the glycolytic pathway. We were able to verify an increase in hexokinase-II expression in our
RYGB model, supporting the claims made my Saeidi et al 4, but were not able to identify any
change after VSG. It is therefore unlikely that glucose metabolism in the intestines is
significantly altered after VSG.
Our study does have a few limitations. First, we have only looked at one time point
approximately 3 months after surgery. It is possible that hyperplasia and altered glucose
metabolism exist earlier in the postoperative period. However, in RYGB animals these effects
have been observed in both the early postoperative period and as late as 12 months after surgery
9,14

. Due to the similar long term effects of both RYGB and VSG on reduced body weight, we

would expect intestinal hyperplasia to persist after VSG if it was a major mechanism of action. A
second limitation is that we did not verify the altered gut hormone secretion and improved
glucose homeostasis observed in other rodent models of VSG. However, our model has similar
body weight, body composition, and food intake profiles when compared to other VSG models
that have been more completely characterized. We therefore find it unlikely that the metabolic
profile of our VSG model is significantly different than those that have been reported. Despite
these limitations, we have provided significant evidence showing that there is no intestinal
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adaptation or altered glucose metabolism in rodents after VSG. It is therefore unlikely that this is
the common mechanism shared by RYGB and VSG to improve body weight and glucose
homeostasis in obese patients. It remains to be seen if these surgeries work through different
mechanisms, or if they share a mechanism that has yet to be identified.
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CHAPTER 4: DISCUSSION
4.1 Key Findings
Gastric bypass surgery remains the only weight loss solution that is effective long term 1.
Despite this, little is known about the mechanisms through which the surgery elicits its effects. In
this thesis, I characterized and compared the adaptive response of the intestines following RYGB
and VSG to test two major hypotheses that have been proposed regarding these surgeries. The
first major hypothesis is that adaptive hyperplasia of the intestines following RYGB is
responsible for improved body weight and glucose homeostasis. How this is achieved is
unknown, but it has been suggested that adaptive hyperplasia may reprogram intestinal glucose
metabolism leading to an anabolic metabolic profile 2. The intestines then become a glucose sink
helping the body to maintain healthy blood glucose levels and aiding in weight loss. It is also
possible that an altered gut hormone secretion profile following RYGB leads to complex
interactions that ultimately reduce body weight and improve glucose homeostasis; however, this
claim has not been well supported in the literature. The second major hypothesis that has
emerged is that both RYGB and VSG, similar but ultimately different surgeries, work through a
common mechanism of action 3. This has been suggested due to the fact that body weight, food
intake, gut hormone secretion profile, glucose metabolism, and long term retention of weight loss
are nearly identical in humans and rodents undergoing either surgery 4,5. Because VSG is much
less invasive and requires much less surgical skill to perform, a number of labs have begun using
animal models of VSG in place of RYGB in order to study the effects of gastric bypass in
general 6. However, there has been no mechanistic evidence to this point that has shown that the
two surgeries actually share a mechanism of action. Here, we outlined data that shows that these
two major hypotheses are mutually exclusive.
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We have shown that there is significant intestinal hyperplasia following RYGB, and that
this may lead to improvements in body weight and glucose homeostasis through a number of
potential mechanisms (Chapter 2). We have also shown that intestinal hyperplasia and a
reprogramming of intestinal glucose metabolism is absent in rats following VSG, and that this
cannot be a mechanism of action for that surgery (Chapter 3). We are then left with two options:
RYGB and VSG share a common mechanism which does not involve intestinal hyperplasia, or
the two surgeries do not share a mechanism of action. While neither major hypothesis that was
investigated was directly supported or rejected, the realization that both cannot be true will help
direct future research into bariatric surgery.

4.2 Future Directions
The idea that RYGB and VSG do not share a common mechanism is hard to support due
to the overwhelming similarities in surgical outcomes between the two procedures. However, the
two surgeries do have very different effects on the structure and morphology of the digestive
tract (Figure 1.1), and therefore could possibly work through separate mechanisms. The evidence
presented by Saiedi et al clearly shows that there is a significant alteration in glucose metabolism
in the intestines following RYGB, and it is hard to say that this would have no effect on glucose
homeostasis in obese or diabetic patients. Fortunately, this is a problem that can be solved
relatively easily by experiments that restrict adaptive hyperplasia following RYGB. It has been
shown that GLP-2 is the major signal required for the adaptive response of the intestines
following injury or disease, and that blocking GLP-2 signaling prevents adaptive hyperplasia 7.
There already exists a GLP-2 receptor null (GLP-2r-/-) mouse strain that could be used to create a
model of RYGB that does not involve adaptive hyperplasia 8. If hyperplasia and reprogramming
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of glucose metabolism is required to receive the beneficial effects of RYGB, then obese GLP-2r/-

mice would be expected to lose little to no weight following RYGB compared to those

receiving sham surgery. Alternatively, if RYGB surgery is successful in reducing body weight
despite the absence of adaptive hyperplasia, it will be clear that some other mechanism is
required. While neither outcome would help determine what mechanism is at play after VSG,
this experiment would still help elucidate the role of adaptive hyperplasia of the intestines
following RYGB, which is currently a major question in the field of gastric bypass surgery.
If RYGB and VSG do share a common mechanism, it will take a bit more work to
determine what exactly that mechanism is. Currently, the most likely candidates are changes to
the microbiome, bile acid secretion, and/or CNS control of energy balance (reviewed in chapter
1). These three mechanisms do not directly depend on a specific gut morphology, and therefore
may be altered in similar ways despite the differences in gut rearrangement after RYGB or VSG
surgery. The research being done into these three potential mechanisms is extensive and outside
the scope of this thesis, but it will be exciting to see what role they play in bariatric surgery.
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